Max Robotics — Global Service Robot Directory + US Certification

About

Dr. C.H.C. Dejong is a leading figure in surgical oncology, with a primary focus on hepatopancreaticobiliary (HPB) surgery and the advancement of minimally invasive techniques. Their most impactful work stems from the landmark LEOPARD trial, a randomized controlled study comparing minimally invasive distal pancreatectomy to open surgery. This pivotal research, published in 2019 and garnering 55 citations, demonstrated that the minimally invasive approach significantly decreases time to functional recovery. Dr. Dejong’s major contribution lies in rigorously evaluating not just surgical outcomes, but also the cost-effectiveness and disease-specific quality of life associated with these procedures. By providing high-level evidence that challenges traditional open surgery as the default, their work has directly shaped clinical guidelines and patient care pathways. Beyond this trial, Dr. Dejong’s research portfolio consistently explores ways to reduce surgical morbidity and accelerate patient recovery, cementing their reputation as a pioneer in evidence-based, patient-centered HPB surgery. Their dedication to generating robust clinical data continues to influence surgeons and improve outcomes for patients worldwide.